AGL 2043
AGL 2043 is an effective inhibitor of PDGFR (IC50=0.8 μM) and TEL-PDGFR kinases, as well as FLT3 and KIT kinases. AGL 2043 can effectively inhibit porcine cardiac smooth muscle cell proliferation and balloon-induced vascular stenosis, and is suitable for development as an anti-restenotic and anticancer agent[1].
Product Specifications
CAS Number
226717-28-8
UNSPSC
12352005
Target
FLT3; PDGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/agl-2043.html
Smiles
CC(N1C)=NC2=C1C=C3N=CC(C4=CC=CS4)=NC3=C2
Molecular Formula
C15H12N4S
Molecular Weight
280.35
References & Citations
[1]Gazit A, et al. Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorg Med Chem. 2003;11 (9) :2007-2018.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CK1 epsilon (CSNK1E) (NM_001894) Human Over-expression Lysate
C6orf136 (NM_001109938) Human Over-expression Lysate
GLUT-1 (Tumor Progression and Mesothelioma Marker) (GLUT1/3132R), 0.2mg/mL
